Oncorus, Inc. - ONCR STOCK NEWS

Oncorus reported its fourth quarter and full year 2021 financial results, highlighting significant advancements in its viral immunotherapy pipeline. As of December 31, 2021, cash and equivalents totaled $123.9 million. The company presented initial data from the Phase 1 trial of ONCR-177, demonstrating safety and clinical benefits in treating multiple solid tumors. Additionally, Oncorus signed a licensing agreement with Gaeta Therapeutics for locally delivered IL-12. However, the net loss increased to $19.8 million, or $0.77 per share, compared to $11.8 million, or $0.56 per share in the previous year.

Oncorus, Inc. (Nasdaq: ONCR) has promoted Dr. John Goldberg to Chief Medical Officer, effective February 22, 2022. Dr. Goldberg, who has been with the company since 2018 as Senior Vice President of Clinical Development, brings over 15 years of oncology experience. His leadership is expected to propel advancements in their viral immunotherapy candidates, including ONCR-177 and ONCR-GBM, with additional data anticipated later this year. Oncorus aims to leverage its unique dual-platform approach to improve cancer treatment outcomes.

Oncorus, a leader in viral immunotherapies, announced that CEO Theodore Ashburn will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The chat will be available for on-demand viewing starting January 10, 2022, at 7:00 AM ET on Oncorus’ website. The company is advancing intratumoral and intravenous viral immunotherapies, including ONCR-177, ONCR-021, and ONCR-788, aimed at transforming cancer treatment. More information can be found on their website.

Oncorus, Inc. (Nasdaq: ONCR) announced participation in two virtual investor conferences. President and CEO Theodore Ashburn will present at the 33rd Annual Piper Sandler Virtual Healthcare Conference, with a replay available from November 22, 2021, and at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021. Oncorus focuses on next-generation viral immunotherapies aimed at improving cancer treatment outcomes, with key programs including ONCR-177, ONCR-021, and ONCR-788. Webcasts will be accessible on their website, archived for 30 days post-event.

On November 17, 2021, Oncorus, a leader in viral immunotherapies, announced that CEO Theodore Ashburn will present at the Jefferies London Healthcare Conference.

The presentation will be available for on-demand viewing starting on November 18, 2021, at 3:00 a.m. ET on Oncorus' website. A replay will be accessible for 30 days post-event.

Oncorus is advancing therapies like ONCR-177, ONCR-021, and ONCR-788, focusing on innovative delivery methods and significant unmet medical needs in cancer treatment.

Oncorus, Inc. presented promising initial results for ONCR-177, a viral immunotherapy targeting advanced injectable solid tumors, at the SITC Annual Meeting. The Phase 1 study showed ONCR-177 was well tolerated with no dose-limiting toxicities. A recommended Phase 2 dose was established, with three out of eight evaluable patients experiencing clinical benefits. This therapy utilizes a proprietary HSV platform designed to enhance efficacy and safety. Upcoming data reads are set for mid-to-late 2022, focusing on combination therapies and expansion cohorts.

Oncorus announced an exclusive licensing agreement with Gaeta Therapeutics for the use of Interleukin-12 (IL-12) combined with immune checkpoint inhibitors in cancer therapy. The agreement includes an upfront payment of $0.2M and potential milestone payments up to $7.5M. Oncorus's lead product, ONCR-177, is an oncolytic viral therapy targeting multiple solid tumors and is currently in a Phase 1 clinical trial. Initial data from this trial will be presented at the SITC Annual Meeting on November 12-14, 2021.

Oncorus, Inc. (Nasdaq: ONCR) will present initial data from its ongoing Phase 1 clinical trial of ONCR-177, a viral immunotherapy utilizing the oncolytic Herpes Simplex Virus (HSV), at the Society for Immunotherapy of Cancer's 36th Annual Meeting on November 12-14, 2021. The presentation will showcase results from patients with advanced injectable tumors, with data cut-off as of November 1, 2021. A conference call hosted by Oncorus management will occur on November 12 at 8:30 a.m. ET, featuring insights from Dr. Igor Puzanov, a key investigator in the trial.

Oncorus reported its third quarter 2021 results, highlighting ongoing clinical trials and significant developments. The company continues patient enrollment for its Phase 1 trial of ONCR-177, with initial data to be presented at the SITC Annual Meeting on November 12. Oncorus is progressing its Synthetic vRNA candidates, ONCR-021 and ONCR-788, and has completed the first phase of its GMP facility. Cash and equivalents stand at $145.6 million, ensuring operational funding through late 2023. The net loss for Q3 2021 was $16.7 million, improved from $22.4 million a year earlier.